Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing WEE1 inhibitors for ovarian cancer treatment, has announced equity inducement grants. The company granted non-qualified stock options to newly hired employees, including 400,000 shares to James B. Bucher, the new Chief Legal Officer, and 15,000 shares to two additional employees.
The options, granted under the 2022 Inducement Plan, have an exercise price of $1.54 per share and a 10-year term. They will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over three years, subject to continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una società biofarmaceutica in fase clinica che sviluppa inibitori WEE1 per il trattamento del cancro ovarico, ha annunciato premi di incentivo azionario. Ha concesso opzioni azionarie non qualificate ai nuovi dipendenti, tra cui 400.000 azioni al nuovo Direttore Legale James B. Bucher e 15.000 azioni a due ulteriori dipendenti.
Le opzioni, concesse nell’ambito del Piano di Induzione 2022, hanno un prezzo di esercizio di 1,54 USD per azione e una
erogazione di 10 anni. Verranno maturate in quattro anni, con il 25% al primo anno e il restante 75% maturato mensilmente nei tre anni successivi, soggette al continuo impiego.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una empresa farmacéutica biotecnológica en etapa clínica que desarrolla inhibidores de WEE1 para el tratamiento del cáncer de ovario, ha anunciado otorgamientos de incentivos de acciones. Ha concedido opciones sobre acciones no calificadas a los nuevos empleados, incluyendo 400.000 acciones al nuevo Director Legal, James B. Bucher, y 15.000 acciones a otros dos empleados.
Las opciones, otorgadas bajo el Plan de Inducción 2022, tienen un precio de ejercicio de $1,54 por acción y un plazo de 10 años. Se consolidarán con el vesting en cuatro años, con un 25% al finalizar el primer año y el 75% restante vesting mensualmente durante los tres años siguientes, sujeto a la continuidad en el empleo.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), 임상 1상 단계의 생물의약품 회사로 난소암 치료를 위한 WEE1 억제제를 개발하고 있으며, 주식 인센티브 보상을 발표했습니다. 신규 채용 직원들에게 무조건부 주식매수선택권을 부여했고, 신규 최고 법무책임자 James B. Bucher 에게는 40만 주, 다른 두 명의 직원에게는 1만 5천 주를 포함합니다.
이 옵션은 2022년 유인계획에 따라 부여되었으며, 주당 행사가격은 1.54달러이고 유효기간 10년입니다. 4년 동안 베스팅되며, 1년 차에 25%, 남은 75%는 향후 3년간 매월 vesting되며, 고용 지속 조건이 충족되어야 합니다.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), une société biopharmaceutique en phase clinique qui développe des inhibiteurs de WEE1 pour le traitement du cancer de l’ovaire, a annoncé des attributions d’incitations en actions. Elle a accordé des options d’achat d’actions sans qualification à des employés récemment recrutés, dont 400 000 actions au nouveau Directeur Juridique James B. Bucher et 15 000 actions à deux autres employés.
Les options, accordées dans le cadre du Plan d’Induction 2022, ont un prix d’exercice de 1,54 $ par action et une durée de 10 ans. Elles se vestent sur quatre ans, avec 25 % d’acquisition après la première année et les 75 % restants s’acquièrent mensuellement sur les trois années suivantes, sous réserve de l’emploi continu.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), ein klinisch aktives Biopharmaunternehmen, das WEE1-Inhibitoren zur Behandlung von Eierstockkrebs entwickelt, hat Aktienbasierte Incentive-Zuwendungen bekannt gegeben. Das Unternehmen gewährte Optionsscheine ohne Qualifikation an neu eingestellte Mitarbeiter, darunter 400.000 Aktien an James B. Bucher, den neuen Chief Legal Officer, und 15.000 Aktien an zwei weitere Mitarbeiter.
Die Optionen, vergeben unter dem 2022 Inducement Plan, haben einen Aktionspreis von 1,54 USD pro Aktie und eine Laufzeit von 10 Jahren. Sie vesten über vier Jahre, 25% nach dem ersten Jahr und die verbleibenden 75% monatlich über die drei folgenden Jahre, vorbehaltlich fortlaufender Anstellung.
Zentalis Pharmaceuticals (NASDAQ: ZNTL)، شركة أدوية حيوية في مرحلة سريرية تطور مثبطات WEE1 لعلاج سرطان المبيض، أعلنت عن منح حوافز أسهم. منحت خيارات من الأسهم غير المؤهلة للموظفين الجدد، بما في ذلك 400,000 سهم للرئيس القانوني الجديد James B. Bucher و 15,000 سهم لاثنين من الموظفين الآخرين.
تُمنح الخيارات، وفقًا لخطة التحفيز لعام 2022، بسعر ممارسة 1.54 دولار أمريكي للسهم وبمدة 10 سنوات. سيتم تحقيقها على مدى أربع سنوات، مع 25% تحقق في نهاية السنة الأولى و%75 المتبقية تتحقق شهريًا على مدى ثلاث سنوات التالية، رهن الاستمرار في العمل.
Zentalis Pharmaceuticals (纳斯达克代码：ZNTL)，一家处于临床阶段的生物制药公司，正在开发 WEE1 抑制剂用于卵巢癌治疗，现宣布了股票激励授予。公司向新任员工授予了非合格股票期权，其中包括新任首席法务官 James B. Bucher 获得400,000 股，另外两名员工各获得 15,000 股。
这些期权是在 2022 年诱导计划下授予，行权价为 1.54 美元/股，期限为 10 年。它们将分四年归属，第一年归属 25%，其余 75% 将在接下来的三年内按月归属，前提是持续雇佣。
- None.
- None.
SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on October 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted the following equity awards: non-qualified stock options to purchase an aggregate of 400,000 shares of the Company’s common stock to James B. Bucher, JD, who joined the Company as Chief Legal Officer and Corporate Secretary, and non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to two (2) additional newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contacts:
Aron Feingold – VP, IR & Corp Comms
ir@zentalis.com
FAQ
What stock options did Zentalis (ZNTL) grant to its new Chief Legal Officer?
What is the vesting schedule for Zentalis (ZNTL) inducement grants announced on October 1, 2025?
What is the exercise price for Zentalis (ZNTL) stock options granted on October 1, 2025?
What is the purpose of Zentalis' 2022 Inducement Plan?
